Figure 3.

CD38^KO NK cells demonstrate enhanced anti-myeloma function in vivo. (A) Experimental schematic illustrating the treatment schedule. (B) Bioluminescence images show mice in each treatment group at 12, 16, 23, and 31 days after myeloma inoculation. (C) Logarithmic scale and (D) linear scale of bioluminescent quantification of MM.1S myeloma tumor growth across all time points (n=5 in all groups except n=4 in the no treatment group). Statistics determined with the Student’s t-test, two tailed, *p<0.05, **p<0.01, ****p<0.0001. DARA, daratumumab; KO, knockout; WT, wild type; MM, multiple myeloma; NK, natural killer.